Holen Sie sich die Stockscreener-App
5.81
3.75%
0.21
Handel nachbörslich:
5.85
0.04
+0.69%
Schlusskurs vom Vortag:
$5.60
Offen:
$5.7
24-Stunden-Volumen:
1.55M
Relative Volume:
1.24
Marktkapitalisierung:
$589.57M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.09M
KGV:
-2.6774
EPS:
-2.17
Netto-Cashflow:
$-138.01M
1W Leistung:
+0.17%
1M Leistung:
-7.78%
6M Leistung:
-33.06%
1J Leistung:
-71.77%
1-Tages-Spanne:
$5.645
$5.995
1-Wochen-Bereich:
$5.575
$5.995
52-Wochen-Spanne:
$5.41
$23.48
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Vergleichen Sie KURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
5.81 | 589.57M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-14 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-08-11 | Eingeleitet | BofA Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-05-17 | Eingeleitet | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Eingeleitet | Jefferies | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
| 2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Transcript : Kura Oncology, Inc.Special Call - MarketScreener
Kura Oncology Announces Positive Phase 1a/1b Trial Results - TipRanks
Long Term Trading Analysis for (KURA) - news.stocktradersdaily.com
Kura Oncology rises after new early-stage trial data for leukemia therapy - MSN
Pallas Capital Advisors LLC Invests $66,000 in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by Harbor Capital Advisors Inc. - Defense World
Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook By Investing.com - Investing.com South Africa
Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook - Investing.com Canada
KURA's Ziftomenib Shows Promising Results in AML Clinical Trial - GuruFocus
Kura Oncology reports positive data for AML treatment ziftomenib By Investing.com - Investing.com South Africa
Is the Options Market Predicting a Spike in Kura Oncology Stock? - The Globe and Mail
Kura Oncology (KURA) Shows Promising Results for AML Therapy - GuruFocus
Kura Oncology Says Ziftomenib Study Achieves Complete Remission in Acute Myeloid Leukemia - MarketScreener
Kura Oncology stock rises on leukemia drug data (KURA:NASDAQ) - Seeking Alpha
Is The Options Market Predicting A Spike In Kura Oncology Stock? - Barchart.com
Kura Oncology and Kyowa Kirin Report Positive Updated Combinatio - GuruFocus
Kura Oncology’s SWOT analysis: ziftomenib stock potential in AML treatment By Investing.com - Investing.com Canada
Kura Oncology and Kyowa Kirin Report Strong Results from KOMET-007 Trial of Ziftomenib in Newly Diagnosed AML Patients - Nasdaq
Kura Oncology reports positive data for AML treatment ziftomenib - Investing.com
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly ... - Enidnews.com
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress - Yahoo Finance
Kura Oncology’s SWOT analysis: ziftomenib stock potential in AML treatment - Investing.com
Cantor Fitzgerald Forecasts Kura Oncology FY2026 Earnings - Defense World
KURA Stock Rises More Than 15% This Past Week: Here's Why - MSN
Kura Oncology at Goldman Sachs Conference: Strategic Insights on ZIFTOMENIB - Investing.com Canada
Transcript : Kura Oncology, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 11 - marketscreener.com
Kura Oncology, Inc. (NASDAQ:KURA) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Ameriprise Financial Inc. Acquires New Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology Stockholders Approve Equity Plan Amendment - TipRanks
Kura Oncology Grants Stock Options To New Hires Under Inducement Plan - Nasdaq
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rul - GuruFocus
Kura Oncology (KURA) Grants Stock Options to New Employees | KUR - GuruFocus
Kura Oncology (KURA) Grants Stock Options to New Employees | KURA Stock News - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KURA Stock News - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Kura Oncology Expands Cancer Research Team with Strategic Stock Options for 5 Key New Hires - Stock Titan
Kura Oncology’s (KURA) “Market Outperform” Rating Reaffirmed at JMP Securities - Defense World
Kura Oncology at Jefferies Conference: Strategic Advancements in AML By Investing.com - Investing.com Canada
**citizens jmp reiterates market outperform rating on kura oncology stock** - Investing.com UK
Two Sigma Investments LP Sells 42,120 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Rising Leaders 2025: Kura Oncology’s Mollie Leoni On Setting Precedent, Not Following It - insights.citeline.com
Nuveen Asset Management LLC Lowers Stock Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Transcript : Kura Oncology, Inc. Presents at American Society of Clinical Oncology Annual Meeting 2025, Jun-02-2025 06 - marketscreener.com
Kura Oncology Drug’s Data at ASCO Support FDA Filing Now Under Priority Review for Leukemia - MedCity News
KURA: Optimism for Kura Oncology's Menin Inhibitor Grows with FDA Priority Review | KURA Stock News - GuruFocus
Cantor Fitzgerald reiterates overweight rating for Kura Oncology stock By Investing.com - Investing.com Nigeria
Kura Oncology reports positive trial results for AML treatment By Investing.com - Investing.com South Africa
Kura Oncology at ASCO: Strategic Moves in AML Treatment By Investing.com - Investing.com Canada
Kura Oncology reports positive trial results for AML treatment - Investing.com Australia
KURA: Promising Results for Kura Oncology's AML Therapy at ASCO Meeting | KURA Stock News - GuruFocus
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kura Oncology Inc-Aktie (KURA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| FORD KATHLEEN | Chief Operating Officer |
May 19 '25 |
Sale |
6.28 |
1,558 |
9,777 |
21,367 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):